Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology

Creative Commons License

Akdis C. A., Bachert C., CİNGİ C., Dykewicz M. S., Hellings P. W., Naclerio R. M., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol.131, no.6, pp.1479-1490, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 131 Issue: 6
  • Publication Date: 2013
  • Doi Number: 10.1016/j.jaci.2013.02.036
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1479-1490
  • Keywords: Chronic rhinosinusitis, endotypes, phenotypes, cytokines, biological agents, treatment, diagnosis, IgE, nasal polyps, pathophysiology, ENDOSCOPIC SINUS SURGERY, STAPHYLOCOCCUS-AUREUS ENTEROTOXINS, NASAL POLYPOSIS, REDUCED EXPRESSION, LOCAL IGE, LONG-TERM, T-CELLS, INFLAMMATION, TISSUE, RESPONSES
  • Eskisehir Osmangazi University Affiliated: Yes


Chronic rhinosinusitis (CRS) is a complex disease consisting of several disease variants with different underlying pathophysiologies. Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of CRS and improving treatment. It is generally agreed that there are clinically relevant CRS phenotypes defined by an observable characteristic or trait, such as the presence or absence of nasal polyps. Defining the phenotype of the patient is useful in making therapeutic decisions. However, clinical phenotypes do not provide full insight into all underlying cellular and molecular pathophysiologic mechanisms of CRS. Recognition of the heterogeneity of CRS has promoted the concept that CRS consists of multiple groups of biological subtypes, or "endotypes," which are defined by distinct pathophysiologic mechanisms that might be identified by corresponding biomarkers. Different CRS endotypes can be characterized by differences in responsiveness to different treatments, including topical intranasal corticosteroids and biological agents, such as anti-IL-5 and anti-IgE mAb, and can be based on different biomarkers that are linked to underlying mechanisms. CRS has been regarded as a single disease entity in clinical and genetic studies in the past, which can explain the failure to identify consistent genetic and environmental correlations. In addition, better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient's endotype, with potential for more effective treatment and better patient outcomes.